Drew Rasco

8.3k total citations · 3 hit papers
192 papers, 4.1k citations indexed

About

Drew Rasco is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Drew Rasco has authored 192 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 121 papers in Oncology, 63 papers in Molecular Biology and 51 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Drew Rasco's work include Cancer Immunotherapy and Biomarkers (57 papers), Monoclonal and Polyclonal Antibodies Research (24 papers) and Lung Cancer Treatments and Mutations (17 papers). Drew Rasco is often cited by papers focused on Cancer Immunotherapy and Biomarkers (57 papers), Monoclonal and Polyclonal Antibodies Research (24 papers) and Lung Cancer Treatments and Mutations (17 papers). Drew Rasco collaborates with scholars based in United States, Japan and Australia. Drew Rasco's co-authors include Kyriakos P. Papadopoulos, Amita Patnaik, Anthony W. Tolcher, Matthew H. Taylor, Corina E. Dutcus, Daniel E. Stepan, Vicky Makker, Emmett V. Schmidt, Robert Shumaker and Muralidhar Beeram and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Drew Rasco

184 papers receiving 4.1k citations

Hit Papers

Lenvatinib plus pembroliz... 2019 2026 2021 2023 2019 2020 2021 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
    2019 360 citations Drew Rasco, Emmett V. Schmidt et al. profile →
  2. Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
    2020 306 citations Drew Rasco et al. Journal of Clinical Oncology profile →
  3. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆
    2021 196 citations Drew Rasco et al. Annals of Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Drew Rasco 2.4k 1.7k 980 870 516 192 4.1k
Carlos Gomez‐Roca 2.4k 1.0× 1.3k 0.8× 820 0.8× 796 0.9× 428 0.8× 147 4.0k
Paul Frankel 1.9k 0.8× 1.8k 1.0× 967 1.0× 388 0.4× 658 1.3× 214 4.1k
Alejandro D. Ricart 2.5k 1.0× 1.4k 0.8× 762 0.8× 780 0.9× 703 1.4× 57 4.0k
Albiruni R. Abdul Razak 2.0k 0.8× 1.1k 0.6× 1.1k 1.1× 639 0.7× 571 1.1× 96 3.5k
Peter Langmuir 1.8k 0.8× 1.3k 0.8× 1.6k 1.7× 888 1.0× 507 1.0× 56 4.7k
Víctor Moreno 3.8k 1.6× 1.8k 1.1× 1.2k 1.2× 847 1.0× 624 1.2× 287 5.5k
J. Thaddeus Beck 2.6k 1.1× 1.3k 0.7× 1.3k 1.3× 525 0.6× 623 1.2× 113 3.7k
Juanita Lopez 2.6k 1.1× 1.9k 1.1× 1.3k 1.3× 1.2k 1.4× 821 1.6× 144 4.9k
Andréa Varga 3.0k 1.3× 1.2k 0.7× 1.2k 1.3× 816 0.9× 547 1.1× 107 4.6k
Colin D. Weekes 2.1k 0.9× 1.4k 0.8× 634 0.6× 379 0.4× 758 1.5× 144 3.5k

Countries citing papers authored by Drew Rasco

Since Specialization
Citations

This map shows the geographic impact of Drew Rasco's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Drew Rasco with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Drew Rasco more than expected).

Fields of papers citing papers by Drew Rasco

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Drew Rasco. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Drew Rasco. The network helps show where Drew Rasco may publish in the future.

Co-authorship network of co-authors of Drew Rasco

This figure shows the co-authorship network connecting the top 25 collaborators of Drew Rasco. A scholar is included among the top collaborators of Drew Rasco based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Drew Rasco. Drew Rasco is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mita, Monica, Alain C. Mita, Miguel A. Villalona‐Calero, et al.. (2024). Abstract PO4-18-07: A dose escalation and cohort expansion study of the CDK9 inhibitor KB-0742 in triple negative breast cancer and transcriptionally addicted relapsed or refractory solid tumors. Cancer Research. 84(9_Supplement). PO4–18. 1 indexed citations
2.
Tolcher, Anthony W., Drew Rasco, Melissa L. Johnson, et al.. (2024). Safety and preliminary efficacy of EIK1001 in combination with pembrolizumab in participants with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 2521–2521. 2 indexed citations
3.
Melero, Ignacio, Judy S. Wang, Martin Gutierrez, et al.. (2024). Cln-619 (anti-MICA/B antibody) alone and in combination with pembrolizumab (P) for advanced solid tumors: Updated results of a Ph1 study.. Journal of Clinical Oncology. 42(16_suppl). 2588–2588. 1 indexed citations
4.
Papadopoulos, Kyriakos P., Manish Sharma, Reinhard Dummer, et al.. (2024). Results of a phase 1, dose-finding study of Debio 0123 as monotherapy in adult patients with advanced solid tumors: Safety, pharmacokinetic, and preliminary antitumor activity data.. Journal of Clinical Oncology. 42(16_suppl). 3120–3120. 5 indexed citations
5.
Sonpavde, Guru, Justin Call, Gerald S. Falchook, et al.. (2024). A first-in-human (FIH), phase 1/2, dose-escalation, dose-optimization, and dose-expansion study of PARP1-selective inhibitor IMP1734 in participants with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). TPS3191–TPS3191. 2 indexed citations
6.
Rasco, Drew, Albiruni Ryan Abdul Razak, Ali Raza Khaki, et al.. (2024). Safety, efficacy, and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced neuroendocrine cancers: Results from a multi-center multi-country phase 1/2a expansion cohort.. Journal of Clinical Oncology. 42(16_suppl). 4129–4129. 1 indexed citations
7.
Kummar, Shivaani, Albiruni R. Abdul Razak, Scott A. Laurie, et al.. (2024). First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies. Cancer Research Communications. 5(1). 94–105. 1 indexed citations
8.
Lakhani, Nehal J., Drew Rasco, Hengbang Wang, et al.. (2023). First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors. Clinical Cancer Research. 30(3). 506–521. 13 indexed citations
9.
Kummar, Shivaani, et al.. (2023). Abstract CT174: First-in-class anti-CD200R1 antibody 23ME-00610 in patients with advanced solid malignancies: Phase 1 results. Cancer Research. 83(8_Supplement). CT174–CT174. 1 indexed citations
10.
11.
Rasco, Drew, Theresa Medina, Pippa Corrie, et al.. (2023). Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma. Cancer Chemotherapy and Pharmacology. 92(1). 15–28. 24 indexed citations
12.
13.
Falchook, Gerald S., Drew Rasco, Kyriakos P. Papadopoulos, et al.. (2023). 128P A phase I dose escalation and expansion trial of LYT-200: A galectin-9 antibody +/- tislelizumab. Immuno-Oncology Technology. 20. 100600–100600. 1 indexed citations
14.
Patnaik, Amita, Erika Hamilton, Drew Rasco, et al.. (2022). A Phase I Dose-Escalation and Dose-Expansion Study of FCN-437c, a Novel CDK4/6 Inhibitor, in Patients with Advanced Solid Tumors. Cancers. 14(20). 4996–4996. 1 indexed citations
15.
Hoff, Daniel D. Von, Drew Rasco, Elisabeth I. Heath, et al.. (2018). Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors. Clinical Cancer Research. 24(17). 4072–4080. 27 indexed citations
16.
Rasco, Drew, Kyriakos P. Papadopoulos, Michael Pourdehnad, et al.. (2018). A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies. Clinical Cancer Research. 25(1). 90–98. 74 indexed citations
17.
Tolcher, Anthony W., Mario Sznol, Siwen Hu‐Lieskovan, et al.. (2017). Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors. Clinical Cancer Research. 23(18). 5349–5357. 183 indexed citations
18.
Patnaik, Amita, Glen J. Weiss, John E. Leonard, et al.. (2015). Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors. Clinical Cancer Research. 22(4). 827–836. 50 indexed citations
19.
Shimizu, Toshio, Patricia LoRusso, K. Papadopoulos, et al.. (2014). Phase I First-in-Human Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2 in Patients with Advanced Solid Tumors. Clinical Cancer Research. 20(19). 5032–5040. 67 indexed citations
20.
Shimizu, Toshio, Anthony W. Tolcher, Kyriakos P. Papadopoulos, et al.. (2012). The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer. Clinical Cancer Research. 18(8). 2316–2325. 352 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carlos Gomez‐Roca Breakdown of academic impact, for papers by Paul Frankel Breakdown of academic impact, for papers by Alejandro D. Ricart Breakdown of academic impact, for papers by Albiruni R. Abdul Razak Breakdown of academic impact, for papers by Peter Langmuir Breakdown of academic impact, for papers by Víctor Moreno Breakdown of academic impact, for papers by J. Thaddeus Beck Breakdown of academic impact, for papers by Juanita Lopez Breakdown of academic impact, for papers by Andréa Varga Breakdown of academic impact, for papers by Colin D. Weekes
Rankless by CCL
2026